Compounds > 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone
Page last updated: 2024-09-03

1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone and Schizophrenia

1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone has been researched along with Schizophrenia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rasmussen, K1
Czachura, JF; Howbert, JJ; Rasmussen, K; Stockton, ME1

Reviews

1 review(s) available for 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone and Schizophrenia

ArticleYear
CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons.
    Annals of the New York Academy of Sciences, 1994, Mar-23, Volume: 713

    Topics: Animals; Anxiety; Brain; Cholecystokinin; Dopamine; Haloperidol; Humans; Neurons; Pyrazoles; Receptors, Cholecystokinin; Schizophrenia

1994

Other Studies

1 other study(ies) available for 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone and Schizophrenia

ArticleYear
Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity.
    European journal of pharmacology, 1991, Dec-10, Volume: 209, Issue:1-2

    Topics: Animals; Antipsychotic Agents; Apomorphine; Cholecystokinin; Dopamine; Male; Mesencephalon; Neurons; Pyrazoles; Rats; Rats, Inbred Strains; Schizophrenia

1991